Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends restricting the use of oral moxifloxacin-containing medicines
Notice type:
Advisory
Date:
01/08/2008
Product name or type:
Moxifloxacin
Active Substance:
Moxifloxacin
Problem Or Issue:
Finalising a review of the safety of moxifloxacin-containing medicines for oral use, the European Medicines Agency (EMEA) has concluded that these medicines should only be prescribed in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed. The Agency also recommended strengthening the warnings for oral moxifloxacin medicines.
Background Information Or Related Documents:
EMEA recommends restricting the use of oral moxifloxacin-containing medicines Document
Further Information:
For further information,
Click Here to read the Press Release and Q&A document
.
« Back
Date Printed: 26/04/2024